Immunotherapy drug avelumab takes on rare thymus cancers
NCT ID NCT03076554
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 7 times
Summary
This phase 2 trial tests the safety and effectiveness of avelumab, an immunotherapy drug, in people with thymoma or thymic carcinoma that has progressed after platinum-based chemotherapy. About 56 participants will receive avelumab intravenously every two weeks. The study aims to see if the drug can shrink tumors or slow disease growth, while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- avelumab (an immunotherapy drug that helps the immune system fight cancer)
- What this could lead to
- If successful, avelumab could offer a new treatment option for people with thymoma or thymic carcinoma that has returned after standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial (56 participants) with no control group. The drug may not shrink tumors or improve survival, and it can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter radiation after thymic tumor surgery may cut side effects
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Talking therapy shows promise for MG patients with depression in tiny pilot study
- Immune cells engineered to hunt thymus cancer show promise in early trial
- Immunotherapy drug nivolumab tested for rare thymus cancers
- New study aims to uncover hidden clues in myasthenia gravis